Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381793 | 1.00 | ADORA1 (0.51) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12036501 | 1.00 | ADORA1 (0.51) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12553231 | 0.94 | ADORA1 (0.51) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12553225 | 0.93 | ADORA1 (0.52) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12020303 | 0.92 | ADORA1 (0.44) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12020312 | 0.92 | ADORA1 (0.44) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12020322 | 0.92 | ADORA1 (0.44) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12553090 | 0.92 | ADORA1 (0.46) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12552918 | 0.92 | ADORA1 (0.47) | ADORA1SLC6A3ADORA2BADORA2AADORA3 | |
| SCHEMBL12552914 | 0.92 | ADORA1 (0.47) | ADORA1SLC6A3ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2379540-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| EP-2185550-B1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2010072314-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072315-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009015776-A1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | ADORA1 1562/4885SLC6A3 671/4885ADORA2B 1900/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | ADORA1 741/4885SLC6A3 476/4885ADORA2B 942/4885 |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | ADORA1 3589/4885SLC6A3 2005/4885ADORA2B 3694/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | ADORA1 2450/4885SLC6A3 2093/4885ADORA2B 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.